

PublisherInfo		
PublisherName	:	BioMed Central
PublisherLocation	:	London
PublisherImprintName	:	BioMed Central

Articles selected in February 2004

ArticleInfo		
ArticleID	:	771
ArticleDOI	:	10.1186/bcr769
ArticleCitationID	:	E12
ArticleSequenceNumber	:	4
ArticleCategory	:	Article selection
ArticleFirstPage	:	1
ArticleLastPage	:	3
ArticleHistory	:	RegistrationDate : 2004-3-3 OnlineDate : 2004-3-3
ArticleCopyright	:	The Author(s)2004
ArticleGrants	:	
ArticleContext	:	130586633

Valerie Speirs, ^{Aff1}

Corresponding Affiliation: ^{Aff1}

Email: v.speirs@leeds.ac.uk

^{Aff1} Molecular Medicine Unit, University of Leeds, St James's University
Hospital, Leeds LS9 7TF, UK

Articles selected from PubMed

References

1. Wang LH, Yang XY, Zhang X, Mihalic K, Fan YX, Xiao W, Howard OM, Appella E, Maynard AT, Farrar WL: Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. *Nat Med.* 2004, 10: 40-47.
2. Santen RJ, Song RX, Zhang Z, Yue W, Kumar R: Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. *Clin Cancer Res.* 2004, 10: 337-345.
3. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM: Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. *Clin Cancer Res.* 2004, 10: 346-354.
4. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA: Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. *Proc Natl Acad Sci USA.* 2004, 101: 1566-1571.
5. Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Kunzer H, Lichtner RB, Nishino Y, Parczyk K, Sauer G, Gieschen H, Ulbrich HF, Schneider MR: Characterization of New Estrogen Receptor Destabilizing Compounds: Effects on Estrogen-Sensitive and Tamoxifen-Resistant Breast Cancer. *J Natl Cancer Inst.* 2004, 96: 210-218.

6. Holmberg L, Anderson H, for the HABITS steering and data monitoring committees: HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. *The Lancet*. 2004, 363: 453-455.
7. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK, Kumar R: p21-activated Kinase-1 Signaling Mediates Cyclin D1 Expression in Mammary Epithelial and Cancer Cells. *J Biol Chem*. 2004, 279: 1422-1428.
8. Reiter R, Oh AS, Wellstein A, Riegel AT: Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta 3 on estrogenic ligands with different intrinsic activity. *Oncogene*. 2004, 23: 403-409.